Results 101 to 110 of about 6,257,121 (349)
WHO'S IN CHARGE? THE RELATIONSHIP BETWEEN MEDICAL LAW, MEDICAL ETHICS, AND MEDICAL MORALITY?
Medical law inevitably involves decision-making, but the types of decisions that need to be made vary in nature, from those that are purely technical to others that contain an inherent ethical content.
C. Foster, J. Miola
semanticscholar +1 more source
Tumor microenvironment drives cancer formation and progression. We analyzed the role of human cancer‐associated adipocytes from patients with renal cell carcinoma (RCC) stratified as lean, overweight, or obese. RNA‐seq demonstrated that, among the most altered genes involved in the tumor–stroma crosstalk, are ADAM12 and CYP1B1, which were proven to be ...
Sepehr Torabinejad+13 more
wiley +1 more source
The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang+3 more
wiley +1 more source
The Possibility of Including Medical Ethics Courses in the Clinical Training of Medicine Students: Academic Members Viewpoints [PDF]
Background & Objective: In spite of supreme goals of Medical Ethics Education it seems that the current Medical curriculum does not have the sufficient capability of influencing attitude and behavior The main purpose of this study was to evaluate the ...
Mohammad Reza Yosefi+3 more
doaj
Basic principles and concept design of a real-time clinical decision support system for managing medical emergencies on missions to Mars [PDF]
Space agencies and private companies prepare the beginning of human space exploration for the 2030s with missions to put the first human on the Mars surface. The absence of gravity and radiation, along with distance, isolation and hostile environments, are expected to increase medical events where previously unseen manifestations may arise. The current
arxiv
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou+11 more
wiley +1 more source
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa+13 more
wiley +1 more source
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu+7 more
wiley +1 more source
Are clinicians ethically obligated to disclose their use of medical machine learning systems to patients? [PDF]
It is commonly accepted that clinicians are ethically obligated to disclose their use of medical machine learning systems to patients, and that failure to do so would amount to a moral fault for which clinicians ought to be held accountable. Call this "the disclosure thesis." Four main arguments have been, or could be, given to support the disclosure ...
arxiv +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock+10 more
wiley +1 more source